Home
Y-Biologics

Y-Biologics Market Share Analysis for August 2026

Exploring Antibodies, Creating Novel Therapeutics 항체신약 연구·개발 분야 전문기업.

Industry: N/A

Domainybiologics.com

Year Founded--

Employees51 - 200

Annual Revenue--

Y-Biologics

Y-Biologics (including company regionals)

ybiologics.com

See more website traffic and engagement information

Total visits to Y-Biologics's top domains

Understand Y-Biologics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

ybiologics.com4.3K

See more with Sales Intelligence

Avg. visit duration in Y-Biologics's top domains

Analyze Y-Biologics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

ybiologics.com00:00:17

See more with Sales Intelligence

Avg. pageviews on Y-Biologics's top domains

See how Y-Biologics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

ybiologics.com1.55

See more with Sales Intelligence

Y-Biologics top competitors by domain

Top similar sites in August 2026, ranked by their affinity

compasspathways.comCompany NameCOMPASS PathwaysEmployees51 - 200HQUnited Kingdom, LondonAnnual revenue$15M - $25MTotal visits55.9KHealth > Addictions

Top technologies used by Y-Biologics

These are the website technologies, by industry, used by Y-Biologics top domains

Mobile (2)

Meta Viewport

Widget (2)

Google Maps

Advertising (1)

PubMatic

Audio Video Media (1)

YouTube

More Technologies

3

See all

News & Signals from Y-Biologics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsY-Biologics is developing LAG-3 inhibitors.In Korea, ABL Bio and Y-Biologics are working on LAG-3 inhibitors.

NewsY-Biologics is developing YBL-013 based on ALiCE platform technology in Greater China on Dec 7th '20.Y-Biologics and 3D Medicines have recently entered into a license agreement to develop, manufacture, and commercialize YBL-013 based on ALiCE platform technology in Greater China.

NewsBiotechin partners with Y-Biologics.« Innovation in oncology is one of its strategic priorities, therefore Biotechin is very excited to partner with Y-Biologics in the discovery and development of cutting-edge monoclonal antibodies.